Misonix net sales increase 36% to $5.6 million in second quarter fiscal 2015

Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced financial results for the second quarter of fiscal 2015, ended December 31, 2014.

Highlights for the second quarter fiscal 2015 included:

  • Net sales totaled $5.6 million, a 36% increase, compared to $4.1 million for the same period in fiscal 2014.
  • BoneScalpel revenue worldwide increased 41% to $3.0 million versus $2.1 million in the second quarter of fiscal 2014.
  • BoneScalpel units consigned in the U.S. during the second quarter fiscal 2015 totaled 18 compared to 12 systems; an increase of 50%. Total BoneScalpel units installed in the U.S. are 324.
  • BoneScalpel revenue in the United States increased 93% to $1.7 million in the second quarter fiscal 2015 compared to $876,000 during second quarter fiscal 2014.
  • SonaStar® revenue increased 43% to $1.7 million versus $1.2 million in the second quarter of fiscal 2014.
  • SonaStar units sold worldwide in second quarter fiscal 2015 totaled 25 compared to 15 systems in the second quarter of fiscal 2014, a 67% increase.
  • SonicOne® worldwide disposable revenue increased 96% to $494,000 for the second fiscal quarter of 2015 compared to $252,000 in the second quarter of fiscal 2014.
  • Recurring revenue – comprised of BoneScalpel, SonaStar and SonicOne disposables sales - totaled $3.3 million, or 59% of total second quarter fiscal 2015 revenue, compared to $1.9 million or 46% for the same period in fiscal 2014.
  • Domestic revenue was 53% of total revenue of the second fiscal quarter 2015 versus 44% for the same period in fiscal 2014.

Second Quarter Fiscal 2015 Financial Results

Total revenue for the three months ended December 31, 2014 was $5.6 million, a 36% increase, when compared to $4.1 million for the same period in fiscal 2014. The increase was attributable to a 41% increase in BoneScalpel revenue to $3.0 million, a 43% increase in SonaStar revenue to $1.7 million and a 57% increase in SonicOne revenue to $840,000.

There were 63 BoneScalpel units sold or consigned worldwide during second quarter fiscal 2015 compared to 57 BoneScalpel units sold or consigned during the second quarter of fiscal 2014. BoneScalpel disposable sales in the United States increased 129% to $1.5 million during second quarter fiscal 2015 compared to the same period in fiscal 2014. There were 25 SonaStar units sold worldwide during second quarter fiscal 2015 compared to 15 SonaStar units sold during the second quarter of fiscal 2014. SonicOne disposable revenue increased 96% to $494,000 for the second quarter of fiscal 2015.

During the quarter, the Company received other income in the form of royalty payments from Covidien plc totaling $1.0 million.

The Company reported net income of approximately $901,000, or $0.11 earnings per diluted share, for second quarter fiscal 2015 compared to a net income of $459,000, or $0.06 earnings per diluted share, for the same period in fiscal 2014.

Six Months Fiscal 2015 Financial Results

Total revenue for the six months ended December 31, 2014 was $10.1 million, a 41% increase, when compared to $7.2 million for the same period in fiscal 2014. The increase was attributable to a 50% increase in BoneScalpel revenue to $5.2 million, a 39% increase in SonaStar revenue to $3.2 million and a 43% increase in SonicOne revenue to $1.4 million.

The Company reported net income of approximately $1.3 million or a $0.16 earning per diluted share for the six months ended December 31, 2014 compared to a net loss of ($425,000) or $.06 loss per share for the same period in fiscal 2014.

Michael A. McManus Jr., President and CEO stated, "We are off to a very strong start for the first half of fiscal 2015. We are particularly pleased with the strong revenue increase across our BoneScalpel, SonicOne and SonaStar product lines in the U.S. where units are mainly consigned. We have made great progress in getting our products accepted as a major instrument in an expanded number of medical institutions throughout the country. In addition to strong U.S. results, we experienced sales growth across virtually all international regions. Our internal sales team and our international distributors continued their excellent performance in the first half of fiscal 2015."

Mr. McManus continued, "As evidenced by the results of the quarter, our ultrasonic surgical instruments are achieving higher levels of acceptance by hospitals and surgeons around the world. The safety profile of our BoneScalpel, resulting in less blood loss, less bone fragmentation and reduction in overall time required to complete a surgical procedure, is gaining increased recognition. The same can be said of our SonaStar and SonicOne products. With the SonicOne we have shown a better way to debride a wound to preserve live tissue with less bleeding and a reduction in bacteria. We have also established a real benefit in the treatment of burns including a recent paper from the Saint Barnabas Medical Center in Livingston, NJ. We are making consistent progress in broadly introducing our products to surgeons around the world and having those products take their rightful place in the surgical suites in which they operate."

Mr. McManus concluded, "The momentum that we developed during fiscal 2014 continued into the first half of fiscal 2015, and we look to extend that into the second half. We maintain a strong cash position of approximately $8.3 million, we carry no long-term debt, and we continue to fund operations from internally generated cash flow. We look forward to continuing to drive solid operational and financial results throughout the rest of fiscal 2015."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New consensus provides evidence-based guidelines for second-degree burns